profit from every $100 of sales.
$0$100
The Joint
$6.94+3.74% today
-16.0% in 1 year
1-year low $6.651-year high $10.53
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $32.68 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What The Joint sold, what it kept, and what it did with the cash.
Sales went from $101 million in 2022 to $54.9 million in 2025, with $2.91 million of profit last year.
SalesProfit
The Joint handed back more cash to shareholders than it generated last year.
Buybacks $11M
Free cash flow 2025$334,724
Bought back its own shares$11M
Paid as dividends–
Cash vs. debt$24M vs. $2M
The Joint vs. similar companies
The Joint grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| The Joint | 32.7× · Expensive | ||
 Tenet Healthcare | 16.2× · Fair price | ||
 Solventum | 9.7× · Cheap | ||
 Encompass Health | 24.4× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.6× · Cheap |
AI analysis
An AI analyst reads The Joint's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 101 | 47 | 52 | 55 | |
| 92 | 36 | 41 | 44 | |
| 1 | 0 | -2 | -1 | |
| 8 | 9 | 3 | 1 | |
| 1 | -10 | -6 | 3 | |
| 0.08 | -0.66 | -0.57 | 0.19 | |
| 90.9% | 77.7% | 77.9% | 79.6% | |
| 1.2% | 0.6% | -3.5% | -1.6% | |
| 0.6% | -20.8% | -11.1% | 5.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 93 | 87 | 83 | 61 |
| Cash | 10 | 18 | 25 | 24 |
| Total debt | 26 | 3 | 1 | 2 |
| Total liabilities | 61 | 62 | 62 | 46 |
| 33 | 25 | 21 | 15 | |
| 15 | 15 | 15 | 15 | |
| 1.7% | 0.9% | -6.7% | -4.2% | |
| 1.9% | -39.4% | -28.1% | 19.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 8 | 15 | 9 | 2 | |
| 6 | 5 | 1 | 2 | |
| 2 | 10 | 8 | 0 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 11 | |
| 1 | 2 | 2 | 1 |
Valuation
- 32.7×
- 35.9×
- 0.98
- 8.0×
- 1.7×
- 283.8×
- 90.8×
- 0.4%
- 3.1%
- 0.0%
Profitability
- 79.6%
- -1.6%
- 5.3%
- 4.5%
- 2.3%
- -6.0%
- 16.9%
- 5.6%
- 2.4%
- –
Growth
- −18.5%
- +33.4%
- −95.9%
- –
- +1.4%
Financial health
- -7.7×
- 0.13
- 3.5%
- –
- 1.61
- 1.61
- 0.98
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 38%of 952
Bottom 19%of 884
Bottom 39%of 601
Bottom 5%of 887
Bottom 42%of 987
What analysts expect
- Average price target
- $20.00
- Range
- $20.00 – $20.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.08 | 0.03 | +166.7% |
| Mar 12, 2026 | 0.06 | 0.05 | +20.0% |
| Nov 6, 2025 | 0.02 | -0.01 | +300.0% |
| Aug 7, 2025 | -0.06 | -0.07 | +14.3% |
| May 8, 2025 | -0.03 | -0.02 | −50.0% |
| Mar 13, 2025 | 0.06 | 0.06 | +0.0% |
| Nov 7, 2024 | 0.04 | -0.00 | +2,731.6% |
| Aug 8, 2024 | -0.06 | -0.01 | −629.9% |
News
Chevron outlines plan to double Venezuela joint venture output to ~600,000 bpd by 2031Seeking Alpha · Oct 30, 2026Big business warns Trump against diesel export ban in joint letterCNBC · Sep 24, 2026This Overlooked Pipeline Stock Just Became a Rival's Joint-Venture Partner Without Anyone NoticingYahoo Finance · Sep 20, 2026Iran and Oman discuss joint shipping route in Strait of Hormuz and mine clearing missionCNBC · Aug 25, 2026Trump scaling down U.S.-South Korea drills could risk more than just joint military readinessCNBC · Aug 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
30No pass
Philip Fisher
52No pass
Peter Lynch
74Pass
Joel Greenblatt
9No pass
Charlie Munger
37No pass
Terry Smith
31No pass
Questions about The Joint
Is The Joint a good stock to buy?
A business with weak numbers, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the The Joint AI analysis
What does The Joint do?
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. It is in Medical - Care Facilities.
Does The Joint pay a dividend?
No. The Joint does not pay a dividend at the moment; in 2025 it returned $11.3 million to shareholders by buying back its own shares.
Is The Joint stock halal?
Yes. The Joint passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has The Joint stock done over the past year?
Down 16.0% over the past twelve months, to $6.94. It traded between $6.65 and $10.53 and is 34.1% below its high.
Who are The Joint's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with The Joint's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.